Free cash flow remains persistently negative, with the company burning between $18.5 million and $50.5 million per quarter, highlighting a structural inability to generate internal liquidity.
| Cash from Operations | -118.41M | -128.54M | -194.25M | -168.59M | -156.67M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | 58.82% | 33.82% | -15.22% | -7.61% | - |
| Net Income | -119.1M | -128.51M | -207.45M | -189.81M | -175.43M |
| Depreciation & Amortization | 3.66M | 3.51M | 2.57M | 1.54M | 1.47M |
| Stock-Based Compensation | 54K | 5.08M | 24.11M | 11.93M | 11.5M |
| Deferred Taxes | 0 | 0 | 0 | -15.01M | -14.45M |
| Other Non-Cash Items | 6.19M | -2.58M | 0 | 15.01M | 14.45M |
| Working Capital Changes | -9.21M | -6.05M | -13.48M | 7.75M | 5.79M |
| Change in Receivables | 1.39M | 5.5M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 65.98M | -25.33M | -3.45M | -5.51M | -4.38M |
| Capital Expenditures | -38K | -92K | -3.45M | -5.51M | -4.38M |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 847K | 67K | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 28K | 196K | 468.81M | 174.1M | 161.05M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 28K | 196K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 468.81M | 174.1M | 161.05M |
| Net Change in Cash | -52.41M | -153.68M | 271.11M | 0 | 0 |
| Free Cash Flow | -118.45M | -128.64M | -197.7M | -174.1M | -161.05M |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | 15.84% | 34.93% | -13.56% | -8.1% | - |
| FCF per Share | -6.84 | -7.59 | -11.85 | -10.43 | -9.65 |
| FCF Conversion (FCF/Net Income) | 0.99x | 1.00x | 0.94x | 0.89x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding exhaustion
According to recent financial filings, Mural Oncology's OCF/NI ratio has exhibited extreme volatility, reaching 4.99 in 2025Q3, which suggests that reported net income is a poor proxy for the actual cash resources being consumed by the company's ongoing clinical development and operational activities.
The significant divergence between net income and operating cash flow indicates that non-cash items and working capital adjustments are heavily distorting the bottom line. Investors should monitor this gap, as it implies that the company's accounting losses may not fully capture the intensity of the cash burn required to maintain its R&D pipeline.
As reported in financial statements, Mural Oncology's free cash flow remains consistently negative, with the company burning approximately $18.5 million to $50.5 million per quarter, highlighting a structural inability to generate internal liquidity while the firm remains in its pre-revenue clinical-stage development phase.
The trajectory of free cash flow shows no signs of stabilization, reflecting the high fixed costs associated with late-stage clinical trials. This persistent cash outflow warrants further investigation into the company's long-term funding strategy, as the current burn rate appears to be accelerating the depletion of available capital reserves.
Based on Mural Oncology's reported figures, working capital changes have been highly erratic, swinging from a $11.1 million inflow in 2025Q2 to a $16.0 million outflow in 2025Q3, which complicates the predictability of the company's short-term cash requirements and overall liquidity management.
These fluctuations suggest that the timing of clinical trial payments and vendor obligations is creating significant noise in the cash flow statement. Such instability may indicate that the company is struggling to manage its payables efficiently, potentially leading to liquidity crunches during periods of high trial activity.
Data from recent filings indicates that Mural Oncology's cash flow statement is heavily influenced by non-cash stock-based compensation adjustments, which peaked at $15.2 million in 2023Q4, obscuring the true economic cost of talent retention during the company's transition to an independent entity.
The reliance on equity-based compensation to preserve cash is a common strategy for biotech firms, but it may mask the true operational burn rate. Analysts should be cautious, as the eventual dilution from these grants could impact shareholder value even if the cash burn appears temporarily mitigated.
Quick answers to the most common questions about buying MURA stock.
Mural Oncology plc (MURA) generated $-128.5M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Mural Oncology plc (MURA) reported negative free cash flow of $128.6M in 2024, indicating capital requirements exceeded cash from operations.
Mural Oncology plc (MURA) spent $0.1M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.